<DOC>
	<DOCNO>NCT01061385</DOCNO>
	<brief_summary>The study evaluate safety efficacy ReShape Intragastric Balloon adjunct diet exercise obese patient compare diet exercise alone . The study device design occupy space within stomach induce satiety . After approval institutional review board , patient provide write consent randomize treatment group ( endoscopic placement study device ) control group ( placement study device ) unblinded basis . Both group receive similar diet exercise counseling . After 24 week , device remove . Patient weight , adverse event , quality life data evaluate throughout 48 week study duration .</brief_summary>
	<brief_title>The Safety Efficacy ReShape Intragastric Balloon Obese Subjects</brief_title>
	<detailed_description />
	<criteria>1 . Subjects age ≥ 20 year ≤ 60 year ; 2 . At screen , body mass index ( BMI ) ≥ 30 Kg/m^2 ≤ 40 Kg/m^2 ; 3 . Have history obesity ( BMI ≥ 30 kg/m^2 ) least 6 month fail weightreduction alternative , supervise diet , exercise behavioral modification program ; 4 . Subject willing commit longterm low calorie ( 10001500 calories/day ) supervise diet ; 5 . Subject reasonable weight loss expectation ( accept goal lose 15 % body weight 24 week ) ; 6 . At screen , total Beck Depression Inventory ( BDI ) score &lt; 12 point , BDI affective subscale score &lt; 7 point . 7 . Subject able follow requirement outline protocol , include comply visit schedule , willing undergo protocolspecific procedure , e.g. , endoscopy , local sedation , general anesthesia , electrocardiography ( ECG ) , and/or clinical laboratory testing ; 8 . Subject willing take prescribe proton pump inhibitor ( PPIs ) ; 9 . Subject able provide write informed consent ; 10 . If female childbearing potential , subject willing use contraception ( e.g. , birth control pill , condom , abstinence ) avoid pregnancy study . 1 . Participating organized weight loss program ( e.g. , Weight Watchers ) ; 2 . Parkinson 's disease ; 3 . Chronic narcotic use ; 4 . Clinically relevant abdominal adhesion ( e.g. , history bowel obstruction ) ; 5 . History symptom gastrointestinal ( GI ) surgery ( exclude uncomplicated appendectomy cholecystectomy ) , obstruction , and/or adhesive peritonitis ; 6 . History symptom clinically significant esophageal GI motility disorder ; 7 . A hormonal genetic cause subject 's obesity ; 8 . A history myocardial infarction previous 6 month , current New York Heart Association ( NYHA ) Functional Class III IV ( heart failure ) cardiac arrhythmia ( e.g. , atrial fibrillation ) ; 9 . History symptom varix , bowel obstruction , congenital acquire GI anomaly ( e.g. , atresia , stenosis , stricture , and/or diverticulum ) , severe renal , hepatic , and/or pulmonary disease ; 10 . History symptom inflammatory bowel disease , Crohn 's disease ; 11 . History symptom uncontrolled unstable thyroid disease ; 12 . Subjects positive breath test Helicobacter pylorus screening ; 13 . History symptom past 12 month significant irritable bowel disease , peritonitis , active esophagitis , gastric duodenal ulceration , GI bleeding ; 14 . History esophageal and/or stomach cancer . 15 . Type I diabetes ; 16 . Placement previous intragastric balloon similar device associate adverse ; endogastric procedure within last 6 month ; 17 . Ongoing treatment anticoagulant , steroid , aspirin ( &gt; 81 mg/day ) , nonsteroidal antiinflammatory drug ( NSAIDS ) , medication know gastric irritant reduce GI motility , unwillingness discontinue use concomitant medication ; 18 . Concomitant use prescription , nonprescription , overthecounter weight loss medication supplement time study ; 19 . Evidence untreated psychiatric eating disorder , major depression , schizophrenia , substance abuse , binge eat disorder , bulimia ; 20 . Pregnancy , breast feeding , intention become pregnant study ( female childbearing potential ) ; 21 . Known allergy silicone ; 22 . A history anemia 23 . Participation another investigational trial within 1 month screening plan enrollment study period . 24 . Presence peptic ulceration , hiatal hernia ( &gt; 2 cm ) , patulous pyloric channel , erosive esophagitis , varix , angiectasia , Barrett 's esophagus finding deem exclusionary opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>